<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
      <PMID Version="1">33240390</PMID>
      <DateRevised>
        <Year>2020</Year>
        <Month>11</Month>
        <Day>27</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Print">1745-1981</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>9</Volume>
            <PubDate>
              <Year>2020</Year>
            </PubDate>
          </JournalIssue>
          <Title>Drugs in context</Title>
          <ISOAbbreviation>Drugs Context</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Emerging systemic JAK inhibitors in the treatment of atopic dermatitis: a review of abrocitinib, baricitinib, and upadacitinib.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">2020-8-5</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.7573/dic.2020-8-5</ELocationID>
        <Abstract>
          <AbstractText>The Janus kinases (JAK) are a group of molecules, composed of JAK1, JAK2, JAK3, and tyrosine kinase 2 (TYK2), which are key components within the JAK-signal transducers and activators of transcription pathway, where cytokine receptor signaling takes place. These molecules play a foundational role in the underlying pathogenesis of multiple immune-related conditions such as atopic dermatitis (AD), rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and others. Thus far, JAK inhibitors for inflammatory conditions have only been marketed for the treatment of rheumatoid arthritis and psoriatic arthritis, but ongoing phase II and phase III clinical trials for other immune-mediated diseases, such as AD, have also shown promising results. This review summarizes the clinical data available from various trials and reports on the safety and efficacy of abrocitinib, baricitinib, and upadacitinib, the three oral systemic JAK inhibitors used in the treatment of AD. The safety and efficacy of JAK inhibitors for the treatment of AD are emerging in the literature. It is important that dermatologists are aware of any potential adverse events or risks associated with the use of JAK inhibitors in order to promote a higher standard of treatment and quality of living.</AbstractText>
          <CopyrightInformation>Copyright © 2020 Nezamololama N, Fieldhouse K, Metzger K, Gooderham M.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Nezamololama</LastName>
            <ForeName>Novin</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Skin Centre for Dermatology, Peterborough, ON, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fieldhouse</LastName>
            <ForeName>Keira</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Skin Centre for Dermatology, Peterborough, ON, Canada.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Trent University, Peterborough, ON, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Metzger</LastName>
            <ForeName>Kristy</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Skin Centre for Dermatology, Peterborough, ON, Canada.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Trent University, Peterborough, ON, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gooderham</LastName>
            <ForeName>Melinda</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Skin Centre for Dermatology, Peterborough, ON, Canada.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Probity Medical Research, Waterloo, ON, Canada.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Queen's University, Kingston, ON, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>11</Month>
          <Day>16</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Drugs Context</MedlineTA>
        <NlmUniqueID>101262187</NlmUniqueID>
        <ISSNLinking>1740-4398</ISSNLinking>
      </MedlineJournalInfo>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">JAK inhibitors</Keyword>
        <Keyword MajorTopicYN="N">JAK1</Keyword>
        <Keyword MajorTopicYN="N">JAK2</Keyword>
        <Keyword MajorTopicYN="N">abrocitinib</Keyword>
        <Keyword MajorTopicYN="N">atopic dermatitis</Keyword>
        <Keyword MajorTopicYN="N">baricitinib</Keyword>
        <Keyword MajorTopicYN="N">eczema</Keyword>
        <Keyword MajorTopicYN="N">upadacitinib</Keyword>
      </KeywordList>
      <CoiStatement>Disclosure and potential conflicts of interest: KF, KM, and NN declare no conflicts of interest. MG has been an investigator, speaker, consultant or advisory board member for AbbVie, Amgen, Akros, Arcutis, Boehringer Ingelheim, BMS, Celgene, Dermira, Dermavant, Galderma, GSK, Eli Lilly, Incyte, Janssen, Kyowa Kirin, Leo Pharma, Medimmune, Merck, Novartis, Pfizer, Regeneron, Sanofi Genzyme, Sun Pharma, UCB, and Valeant/Bausch. The International Committee of Medical Journal Editors (ICMJE) Potential Conflicts of Interests form for the authors is available for download at: https://www.drugsincontext.com/wp-content/uploads/2020/10/dic.2020-8-5-COI.pdf</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>8</Month>
          <Day>9</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>2</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>5</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>11</Month>
          <Day>26</Day>
          <Hour>5</Hour>
          <Minute>46</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>11</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2020</Year>
          <Month>11</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33240390</ArticleId>
        <ArticleId IdType="pmc">PMC7673622</ArticleId>
        <ArticleId IdType="doi">10.7573/dic.2020-8-5</ArticleId>
        <ArticleId IdType="pii">dic-2020-8-5</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Villarino AV, Kanno Y, O’Shea JJ. Mechanisms and consequences of Jak–STAT signaling in the immune system. Nat Immunol. 2017;18(4):374–384. doi: 10.1038/ni.3691.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ni.3691</ArticleId>
            <ArticleId IdType="pubmed">28323260</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sonbol MB, Firwana B, Zarzour A, Morad M, Rana V, Tiu RV. Comprehensive review of JAK inhibitors in myeloproliferative neoplasms. Ther Adv Hematol. 2013;4(1):15–35. doi: 10.1177/2040620712461047.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/2040620712461047</ArticleId>
            <ArticleId IdType="pmc">PMC3629759</ArticleId>
            <ArticleId IdType="pubmed">23610611</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>He H, Guttman-Yassky E. JAK inhibitors for atopic dermatitis: an update. Am J Clin Dermatol. 2019;20(2):181–192. doi: 10.1007/s40257-018-0413-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s40257-018-0413-2</ArticleId>
            <ArticleId IdType="pubmed">30536048</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Damsky W, King BA. JAK inhibitors in dermatology: the promise of a new drug class. J Am Acad Dermatol. 2017;76(4):736–744. doi: 10.1016/j.jaad.2016.12.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jaad.2016.12.005</ArticleId>
            <ArticleId IdType="pmc">PMC6035868</ArticleId>
            <ArticleId IdType="pubmed">28139263</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cosgrove SB, Wren JA, Cleaver DM, et al.  A blinded, randomized, placebo-controlled trial of the efficacy and safety of the Janus kinase inhibitor oclacitinib (Apoquel®) in client-owned dogs with atopic dermatitis. Vet Dermatol. 2013;24(6):587.e142. doi: 10.1111/vde.12088.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/vde.12088</ArticleId>
            <ArticleId IdType="pmc">PMC4286885</ArticleId>
            <ArticleId IdType="pubmed">24581322</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tanimoto A, Ogawa Y, Oki C, et al.  Pharmacological properties of JTE-052: a novel potent JAK inhibitor that suppresses various inflammatory responses in vitro and in vivo. Inflamm Res. 2015;64(1):41–51. doi: 10.1007/s00011-014-0782-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00011-014-0782-9</ArticleId>
            <ArticleId IdType="pmc">PMC4286029</ArticleId>
            <ArticleId IdType="pubmed">25387665</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet. 2020;396(10247):345–360. doi: 10.1016/S0140-6736(20)31286-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(20)31286-1</ArticleId>
            <ArticleId IdType="pubmed">32738956</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bieber T. Atopic dermatitis. N Engl J Med. 2008;358:1483–1494. doi: 10.1056/NEJMra074081.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMra074081</ArticleId>
            <ArticleId IdType="pubmed">18385500</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jamilloux Y, El Jammal T, Vuitton L, Gerfaud-Valentin M, Kerever S, Sève P. JAK inhibitors for the treatment of autoimmune and inflammatory diseases. Autoimmun Rev. 2019;18(11):102390. doi: 10.1016/j.autrev.2019.102390.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.autrev.2019.102390</ArticleId>
            <ArticleId IdType="pubmed">31520803</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Montilla AM, Gómez-García F, Gómez-Arias PJ, et al.  Scoping review on the use of drugs targeting JAK/STAT pathway in atopic dermatitis, vitiligo, and alopecia areata. Dermatol Ther (Heidelb) 2019;9(4):655–683. doi: 10.1007/s13555-019-00329-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s13555-019-00329-y</ArticleId>
            <ArticleId IdType="pmc">PMC6828894</ArticleId>
            <ArticleId IdType="pubmed">31606872</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harrison DA. The JAK/STAT pathway. Cold Spring Harb Perspect Biol. 2012;4(3) doi: 10.1101/cshperspect.a011205.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/cshperspect.a011205</ArticleId>
            <ArticleId IdType="pmc">PMC3282412</ArticleId>
            <ArticleId IdType="pubmed">22383755</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yamaoka K, Saharinen P, Pesu M, Holt VE, Silvennoinen O, O’Shea JJ. The Janus kinases (Jaks) Genome Biol. 2004;5(12):253. doi: 10.1186/gb-2004-5-12-253.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/gb-2004-5-12-253</ArticleId>
            <ArticleId IdType="pmc">PMC545791</ArticleId>
            <ArticleId IdType="pubmed">15575979</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cornez I, Yajnanarayana SP, Wolf AM, Wolf D. JAK/STAT disruption induces immuno-deficiency: rationale for the development of JAK inhibitors as immunosuppressive drugs. Mol Cel Endocrinol. 2017;451:88–96. doi: 10.1016/j.mce.2017.01.035.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.mce.2017.01.035</ArticleId>
            <ArticleId IdType="pubmed">28131742</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cotter DG, Schairer D, Eichenfield L. Emerging therapies for atopic dermatitis: JAK inhibitors. J Am Acad Dermatol. 2018;78(3 Suppl 1):S53–S62. doi: 10.1016/j.jaad.2017.12.019.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jaad.2017.12.019</ArticleId>
            <ArticleId IdType="pubmed">29248518</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haugh IM, Watson IT, Alan Menter M. Successful treatment of atopic dermatitis with the JAK1 inhibitor oclacitinib. Proc (Bayl Univ Med Cent) 2018;31(4):524–525. doi: 10.1080/08998280.2018.1480246.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/08998280.2018.1480246</ArticleId>
            <ArticleId IdType="pmc">PMC6413965</ArticleId>
            <ArticleId IdType="pubmed">30949000</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Samaka RM, Basha MA, Menesy D. Role of Janus kinase 1 and signal transducer and activator of transcription 3 in vitiligo. Clin Cosmet Investig Dermatol. 2019;12:469–480. doi: 10.2147/CCID.S210106.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/CCID.S210106</ArticleId>
            <ArticleId IdType="pmc">PMC6612046</ArticleId>
            <ArticleId IdType="pubmed">31303777</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gooderham MJ, Forman SB, Bissonnette R, et al.  Efficacy and safety of oral Janus kinase 1 inhibitor abrocitinib for patients with atopic dermatitis: a phase 2 randomized clinical trial. JAMA Dermatol. 2019;155(12):1371–1379. doi: 10.1001/jamadermatol.2019.2855.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamadermatol.2019.2855</ArticleId>
            <ArticleId IdType="pmc">PMC6777226</ArticleId>
            <ArticleId IdType="pubmed">31577341</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Simpson EL, Sinclair R, Forman S, et al.  Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: results from the phase 3 JADE MONO-1 study. Paper presented at: Revolutionizing Atopic Dermatitis (RAD) Virtual Conference; April 5, 2020; Chicago, IL. </Citation>
        </Reference>
        <Reference>
          <Citation>Silverberg JI, Simpson EL, Thyssen JP, et al.  Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: results from the phase 3 JADE MONO-2 study. Paper presented at: Revolutionizing Atopic Dermatitis (RAD) Virtual Conference; April 5, 2020; Chicago, IL. </Citation>
        </Reference>
        <Reference>
          <Citation>Pantazi E, Valenza G, Hess M, Hamad B. The atopic dermatitis market. Nat Rev Drug Discov. 2018;17:237–238. doi: 10.1038/nrd.2017.192.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrd.2017.192</ArticleId>
            <ArticleId IdType="pubmed">29104285</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guttman-Yassky E, Thaçi D, Pangan AL, et al.  Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial. J Allergy Clin Immunol.  doi: 10.1016/j.jaci.2019.11.025. Published online November 29, 2019.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jaci.2019.11.025</ArticleId>
            <ArticleId IdType="pubmed">31786154</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>AbbVie. AbbVie’s Upadacitinib (ABT-494) meets primary endpoint in phase 2b study in atopic dermatitis.  [Accessed May 25, 2020].   https://news.abbvie.com/news/abbvies-upadacitinib-abt-494-meets-primary-endpoint-in-phase-2b-study-in-atopic-dermatitis.htm.</Citation>
        </Reference>
        <Reference>
          <Citation>Guttman-Yassky E, Silverberg JI, Nemoto O, et al.  Baricitinib in adult patients with moderate-to-severe atopic dermatitis: a phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study. J Am Acad Dermatol. 2019;80(4):913–921.e9. doi: 10.1016/j.jaad.2018.01.018.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jaad.2018.01.018</ArticleId>
            <ArticleId IdType="pubmed">29410014</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Simpson EL, Lacour J-P, Spelman L, et al.  Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. Br J Dermatol. 2020;183(2):242–255. doi: 10.1111/bjd.18898.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/bjd.18898</ArticleId>
            <ArticleId IdType="pubmed">31995838</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gooderham MJ, Hong HC-H, Eshtiaghi P, Papp KA. Dupilumab: a review of its use in the treatment of atopic dermatitis. J Am Acad Dermatol. 2018;78(3 Suppl 1):S28–S36. doi: 10.1016/j.jaad.2017.12.022.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jaad.2017.12.022</ArticleId>
            <ArticleId IdType="pubmed">29471919</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>JAK compound (inhibitors, antagonists)-ProbeChem.com.  [Accessed September 29, 2020].   http://www.probechem.com/target_JAK.aspx.</Citation>
        </Reference>
        <Reference>
          <Citation>Upadacitinib (ABT-494), ≥99%(HPLC), Selleck, JAK inhibitor. selleckchem.com.  [Accessed September 29, 2020].   https://www.selleckchem.com/products/upadacitinib.html.</Citation>
        </Reference>
        <Reference>
          <Citation>Mayence A, Vanden Eynde JJ. Baricitinib: a 2018 novel FDA-approved small molecule inhibiting Janus kinases. Pharmaceuticals (Basel) 2019;12(1) doi: 10.3390/ph12010037.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ph12010037</ArticleId>
            <ArticleId IdType="pmc">PMC6469186</ArticleId>
            <ArticleId IdType="pubmed">30871014</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Search of: PF-04965842, atopic dermatitis, phase 2, 3 – list results. ClinicalTrials.gov.  [Accessed May 28, 2020].   https://clinicaltrials.gov/ct2/results?term=PF-04965842&amp;cond=Atopic+Dermatitis&amp;age_v=&amp;gndr=&amp;type=&amp;rslt=&amp;phase=1&amp;phase=2&amp;Search=Apply.</Citation>
        </Reference>
        <Reference>
          <Citation>Search of: baricitinib and atopic dermatitis, phase 2, 3 – list results. ClinicalTrials.gov.  [Accessed May 26, 2020].   https://clinicaltrials.gov/ct2/results?cond=baricitinib+and+atopic+dermatitis&amp;age_v=&amp;gndr=&amp;type=&amp;rslt=&amp;phase=1&amp;phase=2&amp;Search=Apply.</Citation>
        </Reference>
        <Reference>
          <Citation>Search of: upadacitinib and atopic dermatitis – list results. ClinicalTrials.gov.  [Accessed May 26, 2020].   https://clinicaltrials.gov/ct2/results?cond=upadacitinib+and+atopic+dermatitis&amp;term=&amp;cntry=&amp;state=&amp;city=&amp;dist=</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
